|LETTERS TO EDITOR
|Year : 2022 | Volume
| Issue : 2 | Page : 89
Comment on An unusual presentation of Vogt-Koyanagi-Harada disease-9
Pradeep Kumar Panigrahi
Department of Ophthalmology, Institute of Medical Sciences and SUM Hospital, SOA (Deemed to be) University, Bhubaneswar, Odisha, India
|Date of Submission||25-May-2021|
|Date of Decision||03-Jun-2021|
|Date of Acceptance||10-Jun-2021|
|Date of Web Publication||18-Jul-2022|
Pradeep Kumar Panigrahi
Department of Ophthalmology, Institute of Medical Sciences and SUM Hospital, SOA (Deemed to be) University, 8-Kalinga Nagar, Bhubaneswar - 751 003, Odisha
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Panigrahi PK. Comment on An unusual presentation of Vogt-Koyanagi-Harada disease-9. J Clin Ophthalmol Res 2022;10:89
With great interest, I went through the article “An unusual presentation of Vogt-Koyanagi-Harada (VKH) Disease” by Keerthhi Dhevi et al. The authors have nicely described an unusual association of subhyaloid hemorrhage with VKH disease. Valsalva retinopathy appears to the most probable cause of the preretinal hemorrhage as mentioned by the authors. The association seems to be coincidental. The association of preretinal hemorrhage with VKH disease is very rare. There are few reports of proliferative retinopathy in cases with VKH disease presenting with preretinal hemorrhage.,, The cause of hemorrhage in such cases is due to the development of retinal neovascularization and is usually seen in chronic recurrent cases of VKH disease. Suboptimal control of inflammation has been postulated to be the cause of retinal neovascularization. Management modalities include adequate control of ocular inflammation with oral steroids and immunosuppressives, laser photocoagulation, antivascular endothelial growth factor agents, and pars plana vitrectomy. VKH disease has a high propensity for recurrence. The authors have managed the present episode with systemic steroids only. Long follow-up will be needed, and if any recurrences develop in the future, combination of systemic steroids with other immunosuppressive agents might be essential. Adequate control of ocular inflammation can help in preventing a rare but possible complication of proliferative retinopathy in VKH disease.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Keerthhi Dhevi RS, Geetha G, Shanker MP, Anusha V. An unusual presentation of Vogt-Koyanagi-Harada disease. J Clin Ophthalmol Res 2021;9:27-9.
To KW, Nadel AJ, Brockhurst RJ. Optic disc neovascularization in association with Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1990;108:918-9.
Kanter PJ, Goldberg MF. Bilateral uveitis with exudative retinal detachment. Angiographic appearance. Arch Ophthalmol 1974;91:13-9.
Magliyah MS, Al-Fakhri AS, Al-Dhibi HA. Proliferative retinopathy as a feature of Vogt Koyanagi Harada Disease: A report of two cases. BMC Ophthalmol 2020;20:470.